Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05862558

Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR

To assess the efficacy and safety of Intravascular Lithotripsy (IVL) in subjects undergoing transfemoral TAVR in patients with severe iliac disease, prohibitive for transfemoral TAVR in patients with severe symptomatic aortic stenosis, otherwise considered for alternative access TAVR. (e.g. trans-carotid)

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The goal of this post-market, prospective, observational single-arm cohort study is to assess the efficacy and safety of Intravascular Lithotripsy (IVL) in subjects undergoing transfemoral TAVR in patients with severe iliac disease, prohibitive for transfemoral TAVR in patients with severe symptomatic aortic stenosis, otherwise considered for alternative access TAVR. (e.g. trans-carotid). This is a study of patients referred to BSW The Heart Hospital, Plano for evaluation of critical aortic stenosis. Those planned to undergo TAVR, have prohibitive iliofemoral disease, and otherwise considered for alternative access, will be considered for the study. The medical devices being used are in the post-market stage as it is being used in accordance with its approved labeling, treating iliofemoral disease.

Study data will be recorded prospectively on dedicated Data Collection Forms and stored locally in a secure format. De-identified data will be uploaded for statistical analysis. IRB approval for the study will be obtained.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 to 90 years of age, inclusive, at the time of signing the informed consent
  • Iliofemoral disease warrants treatment, per routine guidelines (greater than 50% stenosis and heavy calcification of the iliac's).
  • Severe symptomatic aortic stenosis and undergoing a planned TAVR procedure
  • Prohibitive iliofemoral disease, as determined by the diagnostic CT abdomen and pelvis.
  • Subjects can provide written, informed consent.

Exclusion criteria

  • Subject is participating in another research study involving an investigational agent that has not reached the primary endpoint.
  • Subject who has contraindications to IVL
  • Subject who has contraindications or is not eligible for TAVR

Treatment and study plan

Shockwave Balloon

Device

Intravascular lithotripsy (IVL) performed with the Shockwave balloon (Shockwave Medical Inc) enables treatment of calcified stenosis of the peripheral arteries by using sonic pressure waves to selectively disrupt superficial and deep calcium without impacting healthy tissue

Primary outcomes

  1. Acute technical success per the DISRUPT PAD definition at the time of intervention

    Time frame: At time of IVL procedure

    Defined as final residual stenosis ≤30% without flow-limiting dissection (≥ Grade D) of the lesion

  2. Success rate of transfemoral delivery of a TAVR system post IVL within 30 days of treatment

    Time frame: At the time of TAVR procedure

    To know the efficacy of the treatment

Secondary outcomes

  1. Applicable VARC-3 criteria at the time of peripheral intervention for bleeding, access site and access related complications.

    Time frame: At IVL procedure

    To understand the efficacy of the treatment

  2. Major adverse events within 1 year

    Time frame: 1 year after IVL procedure

    need for emergency surgical revascularization of target limb, unplanned target limb major amputation (above the ankle), symptomatic thrombus or distal emboli that requires surgical, mechanical, or pharmacologic means to improve flow and extend hospitalization, perforations that require an intervention, including bail-out stenting.

Sponsors and collaborators

Lead sponsor

Baylor Research Institute

Other

Collaborators

  • Shockwave Medical, Inc.

Registry information

Acronym: ILIT

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
May 17, 2023
Registry last updated
Jan 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.